% | $
Quotes you view appear here for quick access.

Opexa Therapeutics, Inc. Message Board

  • anonymousfeller anonymousfeller Mar 11, 2013 1:22 PM Flag

    The MERCK Option

    Per the PR about the MERCK and OPEXA option agreement, it seems to me that MERCK is interested potentially in Tcelna's effect on MS in general and not just on Tcelna's effect on SPMS. There really could be more news to come. Maybe that institution that bought shares read between the lines the way i am doing right now.

    "Under the terms of the agreement, Opexa will receive an upfront payment of $5 million for granting an option to Merck Serono for the exclusive license of the Tcelna (imilecleucel-T) program for the treatment of MS. The option may be exercised prior to or upon completion of Opexa’s ongoing Phase IIb clinical trial in patients with SPMS. Upon exercising this licensing option, Merck Serono would pay an upfront license fee of either $25 million or $15 million (depending upon whether certain conditions are met), and in return receive worldwide development and commercial rights to Tcelna (imilecleucel-T) in MS, excluding Japan."

    MERCK can exercise at any time now...........

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
4.00+0.13(+3.36%)Jun 24 4:00 PMEDT